Studies investigating a surrogate marker of BBB permeability, namely CSF/serum albumin ratio, have shown in Parkinson’s disease (Liguori et al., 2017), that this ratio increases with disease severity along with amyloid beta (Aβ) and total tau. This evidence concerns the gene ALB and Parkinson disease.